Primary care providers' views on metabolic monitoring of outpatients taking antipsychotic medication

Psychiatric Services

Volumn 64, Issue 6, 2013, Pages 597-599

  Mangurian, Christina ^a   Giwa, Funmi ^a   Shumway, Martha ^a   Fuentes Afflick, Elena ^a   Pérez Stable, Eliseo J ^a   Dilley, James W ^a   Schillinger, Dean ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SFGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; DISEASE SEVERITY; FEMALE; HEALTH PERSONNEL ATTITUDE; HEALTH SURVEY; HUMAN; MALE; MENTAL DISEASE; OUTPATIENT; PATIENT MONITORING; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PUBLIC HEALTH; RESPONSIBILITY; TREATMENT RESPONSE; UNITED STATES;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; CARDIOVASCULAR DISEASES; COMMUNITY HEALTH CENTERS; COOPERATIVE BEHAVIOR; FEMALE; GUIDELINES AS TOPIC; HUMANS; MALE; MENTAL DISORDERS; METABOLIC DISEASES; MIDDLE AGED; OUTPATIENTS; PRIMARY HEALTH CARE; SEVERITY OF ILLNESS INDEX;

EID: 84883187161     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.002542012     Document Type: Article

References (15)

1. Colton CW, Manderscheid RW: Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Preventing Chronic Disease 3:A42, 2006
2. Brown S, Kim M, Mitchell C, et al: Twenty-five year mortality of a community cohort with schizophrenia. British Journal of Psychiatry 196:116-121, 2010
3. Druss BG: Improving medical care for persons with serious mental illness: challenges and solutions. Journal of Clinical Psychiatry 68(suppl 4):40-44, 2007
4. McEvoy JP, Meyer JM, Goff DC, et al: Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research 80:19-32, 2005
5. Newcomer JW, Hennekens CH: Severe mental illness and risk of cardiovascular disease. JAMA 298:1794-1796, 2007
6. Nasrallah HA, Meyer JM, Goff DC, et al: Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research 86:15-22, 2006
7. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596-601, 2004
8. Buckley PF, Miller DD, Singer B, et al: Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophrenia Research 79:281-288, 2005
9. Essock SM, Covell NH, Leckman-Westin E, et al: Identifying clinically questionable psychotropic prescribing practices for Medicaid recipients in New York State. Psychiatric Services 60:1595-1602, 2009
10. Morrato EH, Druss B, Hartung DM, et al: Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Archives of General Psychiatry 67:17-24, 2010
11. Morrato EH, Cuffel B, Newcomer JW, et al: Metabolic risk status and secondgeneration antipsychotic drug selection: a retrospective study of commercially insured patients. Journal of Clinical Psychopharmacology 29:26-32, 2009
12. Arbuckle MR, Gameroff MJ, Marcus SC, et al: Psychiatric opinion and antipsychotic selection in the management of schizophrenia. Psychiatric Services 59: 561-565, 2008
13. Olfson M, Marcus SC, Wilk J, et al: Awareness of illness and nonadherence to antipsychotic medications among persons with schizophrenia. Psychiatric Services 57:205-211, 2006
14. Amiel JM, Pincus HA: The medical home model: new opportunities for psychiatric services in the United States. Current Opinion in Psychiatry 24:562-568, 2011
15. Parameswaran SG, Chang C, Swenson AK, et al: Roles in and barriers to metabolic screening for people taking antipsychotic medications: a survey of psychiatrists. Schizophrenia Research. 143:395-396, 2013